HYPOTHESIS: The addition of WR worn on the lower legs during an on-field warm-up would lead to decreases in relatively high-intensity external TL metrics, such as distance covered >6.11 m∙s-1 and acceleration and deceleration >/<3 m∙s-2 and increases in internal TL during the warm-up, yet would have little effect on the subsequent training session when WR was removed.
STUDY DESIGN: Matched-pair randomized design.
LEVEL OF EVIDENCE: Level 3.
METHODS: A total of 28 soccer players were allocated to either a WR training (WRT = 14) or unloaded (control [CON] = 14) group. Both groups performed the same warm-up and on-field training for 8 weeks, with the WRT group wearing 200 g to 600 g loads on their lower leg during the warm-up. External TL was measured via global positioning system data and internal TL was assessed using session rating of perceived exertion (sRPE × time per session).
RESULTS: No statistically significant between-group differences (P ≥ 0.05) were identified for any TL measurement during either warm-ups or training sessions. Lower leg WR resulted in trivial to moderate effects for all external TL metrics (-16.9% to 2.40%; d = -0.61 to 0.14) and sRPE (-0.33%; d = -0.03) during the warm-up and trivial to small effects on all external TL metrics (-8.95% to -0.36%; d = -0.45 to -0.30) and sRPE (3.39%; d = 0.33) during training sessions.
CONCLUSION: Warming up with lower leg WR negatively affects neither the quality and quantity of the warm-up nor the subsequent training session once WR is removed.
CLINICAL RELEVANCE: Using WR on the lower leg during on-field warm-ups may be a means to "microdose" strength training while not unduly increasing TL. However, further research is needed to determine the influence of WR on strength qualities.
METHODS: We produced two NiV vaccine candidates using the licensed VSV-EBOV vaccine as a backbone and tested its efficacy against lethal homologous and heterologous NiV challenge with Nipah virus Bangladesh and Nipah virus Malaysia, respectively, in the African green monkey model.
FINDINGS: The VSV-EBOV vaccine expressing NiV glycoprotein G (VSV-NiVG) induced high neutralising antibody titers and afforded complete protection from homologous and heterologous challenge. The VSV-EBOV vaccine expressing NiV fusion protein F (VSV-NiVF) induced a lower humoral response and afforded complete homologous protection, but only partial heterologous protection. Both vaccines reduced virus shedding from the upper respiratory tract, and virus replication in the lungs and central nervous system. None of the protected animals vaccinated with VSV-NiVG or VSV-NiVF showed histological lesions in the CNS, but one VSV-NiVF-vaccinated animal that was not protected developed severe meningoencephalitis.
INTERPRETATION: The VSV-NiVG vaccine offers broad protection against NiV disease.
FUNDING: This study was supported by the Intramural Research Program, NIAID, NIH.